Methods and compositions for treating cancer using peptide nucleic acid-based agents
US-10113169-B2 · Oct 30, 2018 · US
US10407469B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10407469-B2 |
| Application number | US-201715476083-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 31, 2017 |
| Priority date | Apr 1, 2016 |
| Publication date | Sep 10, 2019 |
| Grant date | Sep 10, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provided herein are polypeptides that self-assemble into nanoparticles upon binding to nucleic acids. The nanoparticles find use, for example in the delivery of the nucleic acids into cells.
Opening claim text (preview).
The invention claimed is: 1. A polypeptide comprising an assembly domain and a nucleic-acid-binding domain (NABD), wherein the assembly domain comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:2 and SEQ ID NO:12; and wherein upon binding of the NABD to a nucleic acid to form a polypeptide/nucleic acid complex, the assembly domain facilitates self-assembly of the polypeptide/nucleic acid complex into nanoparticles. 2. The polypeptide of claim 1 , wherein the amino acid sequence comprises SEQ ID NO:2. 3. The polypeptide of claim 2 , wherein the amino acid sequence comprises SEQ ID NO:1. 4. The polypeptide of claim 2 , wherein the amino acid sequence comprises SEQ ID NO:5. 5. The polypeptide of claim 1 , wherein the amino acid sequence comprises SEQ ID NO:12. 6. The polypeptide of claim 5 , wherein the amino acid sequence comprises SEQ ID NO:11. 7. The polypeptide of claim 1 , wherein the NABD binds single-stranded (ss) and/or double-stranded DNA and/or RNA. 8. The polypeptide of claim 1 , wherein the NABD and assembly domain are connected by a linker moiety. 9. The polypeptide of claim 1 , further comprising a bioactive domain that enhances one or more characteristics selected from the group consisting of cell internalization, cell-targeting, endosome escape, and nuclear delivery. 10. The polypeptide of claim 9 , wherein the bioactive domain is selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 8, and SEQ ID NO: 10. 11. A carrier nanoparticle comprising: (a) cargo nucleic acids, and (b) polypeptides of claim 1 . 12. The carrier nanoparticle of claim 11 , wherein the cargo nucleic acid is a single stranded or double stranded DNA or RNA. 13. The carrier nanoparticle of claim 11 , wherein binding of the polypeptide to the cargo nucleic acid facilitates self-assembly of the polypeptide/nucleic acid complexes into the carrier nanoparticles. 14. The carrier nanoparticle of claim 11 , wherein the nanoparticle is between 20 and 800 nm in diameter. 15. A method of delivering a cargo nucleic acid into a cell, comprising exposing the cell to a nanoparticle of claim 11 .
containing a domain for self-assembly, e.g. a viral coat protein (includes phage display) · CPC title
containing a tag for extracellular membrane crossing, e.g. TAT or VP22 · CPC title
containing a nuclear localisation signal · CPC title
Cationic antimicrobial peptides, e.g. defensins · CPC title
Marker; Tag · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.